AbbVie Inc. (ABBV)
AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results?
AbbVie ABBV is set to report first-quarter 2026 earnings on April 29, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $14.78 billion and $2.69 per share, respectively.
AbbVie to build $1.4 billion manufacturing campus in North Carolina
AbbVie will invest $1.4 billion to build a manufacturing campus in North Carolina, the drugmaker said on Wednesday, marking its biggest investment to date in a single site.
AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Clarity Financial LLC Sells 23,870 Shares of AbbVie Inc. $ABBV
Clarity Financial LLC lessened its holdings in AbbVie Inc. (NYSE: ABBV) by 11.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 181,985 shares of the company's stock after selling 23,870 shares during the period. AbbVie comprises 3.8% of Clarity Financial
Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma's Most Durable Compounder?
One of Wall Street's top firms just made the bull case for AbbVie (NYSE:ABBV | ABBV Price Prediction) stock, initiating coverage with a Buy rating and a $262 price target.
Here's Why AbbVie (ABBV) Fell More Than Broader Market
AbbVie (ABBV) closed at $203.71 in the latest trading session, marking a -2.24% move from the prior day.
Why I Can't Stop Buying AbbVie Stock
AbbVie (NYSE:ABBV | ABBV Price Prediction) has attracted persistent buying interest, and every pullback has drawn in value-focused investors.
Will AbbVie's Oncology Franchise Weigh on Q1 Top-line Growth?
ABBV's oncology unit faces declining Imbruvica sales and pricing pressure, likely dragging Q1 revenues despite growth from newer cancer therapies.
AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock
AbbVie stock trades below key SMAs, signaling weakness, but strong Skyrizi and Rinvoq growth and a robust pipeline could support a rebound.
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw AbbVie (ABBV) settling at $210.26, representing a +1.84% change from its previous close.
2 dividend stocks to buy after Q1 earnings season
As the Q1 2026 earnings season plays out, the focus is shifting from short-term performance to long-term income potential, with investors zeroing in on companies that continue to reward shareholders consistently through dividends.
